ICD-10-PCS 2027 procedure code
XW043H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
Short description: Introduce Axicab in Central Vein, Perc, New Tech 7
Code last changed in FY2022 (effective October 1, 2021). Source: official FY2027 ICD-10-PCS release from CMS. Page updated September 29, 2026. About our data
About XW043H7
XW043H7 is the ICD-10-PCS code for a introduction procedure on the central vein using a percutaneous approach with axicabtagene ciloleucel immunotherapy (qualifier: new technology group 7). In ICD-10-PCS, introduction means putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.
For a different body part, codes include XW033H7 (peripheral vein).
With a different device, use XW04357 (ifezuntirgene inilparvovec), XW043A7 (ciltacabtagene autoleucel), XW043C7 (recombinant human bone morphogenetic protein-2 with collagen scaffold), XW043G7 (vancomycin hydrochloride and tobramycin sulfate anti-infective, temporary irrigation spacer system), XW043J7 (paclitaxel-coated balloon technology, two balloons), XW043K7 (paclitaxel-coated balloon technology, three balloons) and 3 more.
It is a non-O.R. procedure that is part of the MS-DRG logic for DRG 018 (Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies), under the surgical category “Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies”.
It was added in FY2022, effective October 1, 2021.
What each character means
- 1. Section
- XNew Technology
- 2. Body System
- WAnatomical Regions
- 3. Operation
- 0Introduction
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
- 4. Body Part
- 4Central Vein
- 5. Approach
- 3Percutaneous
Entry, by puncture or minor incision, of instrumentation through the skin or mucous membrane and any other body layers necessary to reach the site of the procedure
- 6. Device / Substance / Technology
- HAxicabtagene Ciloleucel Immunotherapy
Includes: Axicabtagene Ciloleucel; Yescarta(R)
- 7. Qualifier
- 7New Technology Group 7
Other versions of this procedure
Different body part
Different device / substance / technology
- XW04357Ifezuntirgene Inilparvovec
- XW043A7Ciltacabtagene Autoleucel
- XW043C7Recombinant Human Bone Morphogenetic Protein-2 with Collagen Scaffold
- XW043G7Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System
- XW043J7Paclitaxel-Coated Balloon Technology, Two Balloons
- XW043K7Paclitaxel-Coated Balloon Technology, Three Balloons
- XW043L7Paclitaxel-Coated Balloon Technology, Four or More Balloons
- XW043M7Baricitinib
- XW043N7SER-109
Different qualifier
MS-DRG v44.0 grouping
All DRGs →Surgical MS-DRGs this procedure can group to, depending on the principal diagnosis's MDC.
MDC PRE · Pre-MDC · Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2022 (effective 10/1/2021): Added
- No changes since FY2022.
Common questions about XW043H7
Is XW043H7 a valid ICD-10-PCS code for 2027?
- Yes. XW043H7 is valid for inpatient procedures from October 1, 2026 through September 30, 2027.
Is XW043H7 an O.R. procedure?
- No. XW043H7 is designated non-O.R. in MS-DRG v44.0.
What DRG does XW043H7 group to?
- Depending on the principal diagnosis, XW043H7 can group to MS-DRG 018.